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Oral essential aminoacid and ketoacid supplements in children
with chronic renal failure
ROBERT JONES, NEIL DALTON, CHARLES TURNER, KATHRYN START, GEORGE HAYCOCK,
and CYRIL CHANTLER
The Evelina Children's Department, Guy's Hospital, London, United Kingdom
Oral essential aminoacid and ketoacid supplements in children with
chronic renal failure. The effects on growth, body composition, and
metabolism of a protein-restriced diet supplemented with essential
aminoacids, the calcium-ketoacids of valine, leucine, isoleucine, and
phenylalanine, and the calcium-hydroxyacid of methionine, were inves-
tigated in seven growth-retarded children with chronic renal failure.
During 0.4 to 1.0 years of treatment there were significant increases in
growth velocity and upper arm circumference so scores, body cell mass
(intracellular water calculated as tritium space minus corrected sodium
bromide space) and serum transferrin. Blood urea and urea:creatinine
ratio fell in all children. Renal function assessed from plasma creatinine
and 51Cr EDTA clearance did not change significantly. During treat-
ment there was an increase in plasma calcium, high levels necessitating
brief interruption of therapy in two children, and a decrease in plasma
phosphate. Levels of serum parathormone fell in all children, and were
correlated inversely with plasma calcium and positively with plasma
phosphate. Abnormalities compared to control children in blood amin-
oacid and branched-chain ketoacid levels were unaffected by treatment.
These results suggest that a protein-restricted diet supplemented with
essential aminoacids and calcium-keto and hydroxyacids may be useful
to improve linear growth and nutritional status in children with chronic
renal failure, and that a reduction in hyperparathyroidism may be partly
responsible for some of the beneficial effects observed.
Supplementation orale en acides-aminés essentiels et en cétoacides chez
des enfants atteints d'insuffisance rénale chronique. Les effets sur Ia
croissance, Ia composition corporelle, et le métabolisme d'un régime
restreint en protéines, supplémenté avec des acides aminés essentiels et
les cétoacides calciques de la valine, Ia leucine, l'isoleucine et Ia
phCnylalanine et I'hydroxyacide calcique de Ia méthionine ont été
étudiés chez sept enfants atteints de retard de croissance et d'insuffi-
sance rénale chronique. Pendant 0.4 a i .0 an de traitement, il y avait des
augmentations significatives des index de so de Ia vitesse de crois-
sance et de Ia circonférence de Ia partie supérieure du bras, de Ia masse
cellulaire corporelle (l'eau intracellulaire calculée comme étant l'espace
tritium diminué de l'espace bromure de sodium corrigé), et de Ia
transferrine sérique. L'urée sanguine et Ia rapport urée sur créatine a
diminué chez tous les enfants. La fonction rénale mesurée par Ia
créatinine plasmatique et Ia clearence du 51Cr EDTA n'a pas change
significativement. Pendant le traitement il y avait une augmentation du
calcium plasmatique, des valeurs élevées nécessitant une breve inter-
ruption du traitement chez deux enfants et une diminution de Ia
phosphatCmie. Les concentrations de parathormone sérique ont di-
minué chez tous les enfants, et étaient corrClées inversement avec Ia
calcémie et positivement avec Ia phosphatémie. Par rapport aux enfants
contrôles, les anomalies des concentrations d'aminoacides plasma-
tiques et de cétoacides a chaInes branchCes Ctaient inchangées par le
traitement. Ces résultats suggèrent qu'un régime restreint en protéines
supplCmenté avec des aminoacides essentiels et des céto et hydroxya-
cides calciques peut Ctre utile pour améliorer la croissance linéaire et
l'état nutritionnel d'enfants atteints d'insuffisance rénale chronique et
qu'une reduction de l'hyperparathyroIdisme peut étre partiellement
responsable de quelques uns des effets bénéfiques observes.
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Protein-restricted diets supplemented with essential aminoac-
ids (EAA) and their nitrogen free alpha-ketoacid and alpha-
hydroxyacid analogues (KAA) may be of nutritional value to
patients with disorders of nitrogen retention or protein intoler-
ance [1—31. Their use has been shown to facilitate the mainte-
nance of nitrogen equilibrium in adults with chronic renal
failure (CRF) [4, 5], and to reduce hyperammonemia and
improve nitrogen balance in children with inborn urea cycle
enzyme deficiencies [3]. An additional beneficial effect of
EAA/KAA diets shown by some studies in adults with CRF is
preservation or even improvement in renal function [5, 6],
perhaps due to decreased dietary phosphate intake and im-
provement in hyperparathyroidism [6, 7]. Whether or not
EAA/KAA are superior to EAA alone as a nutritional supple-
ment in CRF remains a contentious topic [8]; some studies in
adults on moderately protein-restricted diets [9] and one short-
term study of nitrogen balance in children and daily weight gain
in infants [10] have failed to show any advantages. The long-
term use of EAA/KAA in uremic children has not been de-
scribed. Since severe growth retardation affects the majority of
prepubertal children with advanced CRF [11] and is often
accompanied by evidence of malnutrition and body protein
depletion [12], a diet restricted in protein but supplemented
with EAA/KAA might be beneficial by reducing uremic toxicity
while stimulating protein accretion and linear growth. We have
therefore examined the effects of such a diet on the growth,
body composition and metabolism of a group of children with
advanced CRF on conservative treatment.
Methods
Seven prepubertal children (six boys and one girl) with stable
CRF were studied before and during 0.4 to 1.0 years of
EAAIKAA therapy. Their level of observation and care re-
mained similar throughout. Clinical and dietary data are shown
in Table 1. The diets before and during the study were super-
vised by a pediatric renal dietitian, and assessed monthly from
3-day prospective dietary records compiled by the mothers at
home. Calorie, protein, calcium, and phosphate intakes were
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Table 1. Clinical and dietary data
Patient
no. Diagnosis
Chronological age
years
Pre Post Pre
Bone age
years
Post
GFR
mllmin/1.73 m2
Pre Mid Post
I CRH 5.0 6.0 4.5 4.9 6 5 6
2 CRH 6.3 7.3 5.1 6.0 13a l3a 12a
3 CRH 6.4 7.4 3.3 3.8 9 10 7
4 RN 7.5 7.9 6.9 6.9 6 4 —
5 CRH 8.6 9.6 4.7 5.6 7 6 6
6 RN 9.9 10.9 8.5 8.8 11 12 11
7 CRH 11.9 12.9 7.2 8.6 11 6 7
Mean±sD 9± 3 8±4 8±3
Abbreviation5: CRH, congenital renal hypoplasia; RN, reflux nephropathy.
GFR = 38 x heightaThe value is calculated from formula [281: Plasma creatinine tmo1es/liter
b The value includes calorie supplement.
The value includes EAA/KAA supplement.
P < 0.02
d p < 0.05
}
compared to pretreatment.f <0.001
calculated by computer using standard tables of food composi-
tion as described previously [13]. Calorie and protein intakes
were expressed as percentages of the recommended daily
allowance (RDA) and the minimum requirement for protein
(MRP), respectively [14], both in relation to height age (the age
at which the 50th centile height for normal children [15]
corresponded to the patients height).
Before EAA/KAA treatment an unrestricted diet was eaten.
Four children received energy supplementation with glucose
polymer (Caloreen®, Roussel Laboratories Ltd., London, Unit-
ed Kingdom). The EAA/KAA study diet, begun during a 2-
week hospitalization, was designed to restrict protein intake to
MRP for height age, 20% of this being given as an EAA/KAA
supplement (Scientific Hospital Supplies Ltd., Liverpool, U nit-
ed Kingdom). This contained five EAA, tyrosine, the calcium
salts of the KAA of valine, leucine, isoleucine, and phenylala-
nine, and the calcium hydroxyacid of methionine. Its formula-
tion, shown in Table 2, was based on the EAA composition of
human breast milk [16], with an excess of each KAA based on
an efficiency of conversion to its respective EAA of 50%. The
supplement was taken at mealtimes as sugar-coated granules,
the daily dose (depending on height age) of 5.7 to 8.6 g of
powder providing 0.22 to 0.33 g nitrogen, 10.8 to 16.2 mmoles
calcium, and 4.7 to 7.1 g of EAA/KAA. Calorie intake was
supplemented with Caloreen® to raise intake to at least RDA for
height age. Six children received supplementary vitamin D (1
alpha-hydroxycholecalciferol 10 to 20 nglkg/day in 5, cholecal-
ciferol 1,000 U/kg/day in 1). In view of the risk of hypercalcemia
with the use of calcium-KAA salts [9], vitamin D was discontin-
ued for the first 6 weeks of treatment, then restarted in the
previous dosage. One child (patient no. 6) received no supple-
mentary vitamin D before or during EAA/KAA. Six children
received sodium bicarbonate/sodium chloride for control of
metabolic acidosis and salt wasting and aluminium hydroxide
in a dosage adjusted according to plasma phosphate
concentration.
Anthropometry. Height was measured monthly using a sta-
diometer (Harpenden) and weight by using a beam balance.
Height and growth velocity were expressed as SD scores (sDs,
number of SD above or below the mean) in relation to chrono-
logical age, and to bone age assessed from x-rays of the left
hand and wrist [17]. Control measurements were available for
12 months prior to starting EAA/KAA in five children; in two
children (patients 4 and 6) data were available for the previous 6
months only. Weight was expressed as a percentage of the 50th
centile weight for normal children of the same height (weight for
height index). Normal data for height, weight, and growth
velocity were obtained from the tables of Tanner, Whitehouse,
and Takashi [15]. Upper arm circumference was expressed as a
SDS, with normal data obtained from the study of Cameron [18].
Triceps and subscapular skinfold thickness were measured as
described by Tanner and Whitehouse [19].
Body composition. Total body water (TBW) and extracellular
volume (ECV) were measured before and after 6 months of
EAA/KAA treatment. TBW was measured from the volume of
distribution of tritiated water 4 hr after the intravenous injection
of 1.5 .tCi/kg body weight (estimated whole body radiation dose
6.3 mrad per investigation). Tritium activity was assayed in a
liquid scintillation counter (LKB Walla 81000) after plasma
water extraction by vacuum distillation over acetone and dry
ice [20]. ECV was estimated from the corrected volume of
distribution of intravenously administered sodium bromide 0.4
mmole/kg, plasma bromide at 4 hr after being assayed by
excitation fluorimetry using an analyzer (Nuclear Data 100)
with a cadmium source [21]. Intracellular water, an estimate of
body cell mass, was calculated as TBW minus ECV, and
expressed in liters, and as a fraction of the value predicted for
normal children of the same height using the formula ICW =
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Table 1. (Continued)
Mean daily dietary intakes
Calories %RDA
height age
Protein %MRP
height age
Calcium
mmoles
Phosphate
mmoles
Pre Studyb Pre Studya Pre Studyc Pre Post
149b 154
l4Sb 89
89 92
101' 76
122 139
98b 112
66 74
149
190
152
134
152
112
136
97
122
145
104
114
88
124
7.6
16.5
19.2
13.1
13.2
12.5
13.7
17.2
22.9
28.3
28.9
21.7
17.0
22.0
15.5
31.8
22.7
20.0
23.7
21.5
25.0
10.6
16.3
22.3
19.4
16.2
12.5
17.8
110 105 146 113' 13.7 22.6 22.9 16.Sd
Human breast
milk (16)
G%
Supplement
composition
G%
Daily
dose
mg'
Valine 11.96 — —
KIVA — 15.76 785
Leucine 20.21 — —
KICA — 26.93 1340
Isoleucine 10.00 — —
MEVA — 13.46 670
Tyrosine
Phenylalanine
15 65. 6.57 327
PPA — 7.88 392
Cystine
Methionine
9 13 2.96 147
MBA — 4.60 229
Histidine 5.65 2.96 147
Lysine (acetate) 14.35 9.36 466
Threonine 9.35 7.22 360
Tryptophan 3.70 2.30 115
Calcium, moisture — — 1021
and acetate
Total 100.00 100.00 6000 mg
16
15
14
13
12
11
10
C.)08
S
3.782 (ht3) + 1.753 [22]. Further details of methodology have
been described previously [12].
Metabolic studies. Serum parathyroid hormone (PTH) was
measured pre-EAA/KAA and monthly during the first 6 months
of treatment; in two children measurements up to 9 and 12
months were available. PTH was measured using a double
radioimmunoassay technique [23], the antiserum used (Medical
Research Council 211/32) cross-reacting with both N- and C-
terminal regions of the PTH molecule.
Serum levels of the branched chain ketoacids (BCKAA), a-
keto-isovaleric acid (KIVA), cr-keto-/3-methylvaleric acid
(MEVA, sum of R- and S-isomers), and a-keto-isocapioic acid
(KICA) were measured before and monthly during the first 6
months of treatment by gas-liquid chromatography using nitro-
gen detection as described by Langenbeck et a! [241. Plasma
amino acids were measured as described previously [25]. Sam-
ples were obtained after an overnight fast of 12 hr. Control data
for PTH, BCKAA, and AA levels were similarly obtained in an
unmatched group of eight healthy prepubertal children of
similar age range to the study group.
Nitrogen balance studies were performed on a metabolic
ward in two children before and I month after starting EAA/
KAA. A diet providing RDA calories and MRP for height age
was eaten on each day of the 3-day equilibration and 4-day
balance periods. Methodology has been described previously
[26]. Nitrogen balance was calculated as nitrogen intake minus
the sum of fecal and urinary losses corrected for changes in
body urea pool (change in serum urea nitrogen x tritium space).
Fractional urinary phosphate excretion during the balance
periods was calculated as the product of urinary phosphate and
Table 2. EAA/KAA supplement composition
Boys
Abbreviations: KIVA, u-keto-isovaleric acid; KICA, a-keto-isoca-
proic acid; MEVA, a-keto-/3-methylvaleric acid; PPA, phenylpyruvic
acid; MBA, a-hydroxy-methylthiobutyric acid.
a The value shows daily dose for child with height age of 5.5 years
and minimum protein requirement of 24 g per day.
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Bone age, years
Fig. 1. Height velocity before and during EAAIKAA treatment plotted
on a Tanner centile chart [151 but in relation to bone age. Patient no. 6,
the only female, is shown in a position corresponding to normal height
velocity centiles for girls. Symbols are: • pre-KAA; A post-KAA.
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Table 3. Growth data
Height Growth velocity
% weight SDS upper armSDS chrono-
Patient
cm logical age SOS bone age cm/year SOS bone age for height circumference
no. Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post
1 88.1 95.2 —4.26 —3.77 —3.73 —2.64 5.1 7.1 —1.42 +0.77 94 95 —0.33 +0.15
2 106.2 112.4 —1.94 —1,77 —0.56 —0.43 4.9 6.2 —1.43 +0.22 111 111 +0.82 +1.31
3 100.6 106.3 —3.14 —2.98 +0.90 +1.35 5.2 5.7 —1.73 —1.11 103 113 —0.40 +1.54
4 108.7 110.8 —2.63 —2.60 —2.06 —1.67 3.0 5.3 —3.24 —0.53 100 103 —0.44 —0.08
5 112.2 117.9 —2.93 —2.76 +1.08 +1.16 3.6 5.7 —2.79 —0.50 114 118 +0.24 +0.80
6 119.8 130.0 —2.56 —1.74 —1.36 +0.10 4.5 10.2 —0.79 +3.33 81 98 —1.85 —0.54
7 125.1 131.2 —3.02 —2.79 +0.61 +0.31 3.5 6.1 —3.02 +0.95 112 110 —0.71 —0.61
Mean —2.92 —0.73 —0.26 4.3 6.6b —2.07 +0.440 102 107 —0.38 +0.37a
Abbreviation: sos, standard deviation score.
P<0.05
b P < 0.02 ' compared to pretreatment.
P < 0.005 J
slope clearance of 50 pCi of intravenously administered 51Cr
EDTA [27] (estimated radiation dose to the kidneys 100 mrad),
and calculated in one child from height and plasma creatinine
[28].
Differences between paired and unpaired data were analyzed
using Student's t tests; correlations were calculated by means
of least squares linear regression. The investigations described
here were approved by the Ethical Committee of Guy's Hospi-
tal Medical School; informed parental consent was obtained for
each patient.
Results
Six children were treated with EAA/KAA for 1.0 years;
patient no. 4 received a successful renal transplant after 0,4
year of treatment. Although some children complained of
nausea on commencing the EAA/KAA supplement, this was
overcome by increasing the dose slowly during the first week of
treatment. The diet was otherwise well tolerated. Dietary
intakes are shown in Table 1. Mean caloric intake was un-
changed during EAA/KAA treatment; total protein intake fell
___________ significantly, but only three children managed to reduce mean
protein intake of 110% MRP or below. Protein:calorie ratio on
EAAIKAA (mean 1.73 0.67 SD G per 100 Kcal) was un-
changed compared to pretreatment (2.01 0.03 SD); reduction
P<O.05 in protein intake in some children was associated with a fall in
energy intake despite the prescription of a calorie supplement.
Pre Post Growth. (Fig. 1 and Table 3) Prior to EAA/KAA all the
cw children were growth-retarded for chronological age and had
growth velocities below those expected for bone age. During
EAA/KAA treatment there were highly significant increases in
mean growth velocity, growth velocity SDS for bone age and
height SDS for chronological age. Improvement in height SDS for
bone age (indicating true catch-up growth) was less impressive,
and although values improved in six children, only patients
numbered 1 and 6 had increases of more than one so. The mean
increase was not statistically significant (P = 0.09). Upper arm
circumference SDS increased significantly during treatment.
Weight for height index, and triceps and subscapular skinfold
thickness centiles did not change significantly.
22 —
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Fig. 2. Body composition
treatment.
St
NS
—4
Pre Post
ECV
before and after 6 months of EAA/KAA
plasma creatinine divided by the product of urinary creatinine
and plasma phosphate concentrations.
Plasma urea, creatinine, calcium, phosphate, alkaline phos-
phatase, transferrin, and albumin were measured monthly by
routine laboratory techniques. GFR was measured in six chil-
dren before, at the midpoint, and end of the study from the
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Table 4. Metabolic data (mean levels SD)
Serum
Plasma
calcium
mmoles/liter
Plasma
phosphate
mmoles/liter
parathyroid
hormone
pg/mi
Plasma
urea
mmoles/liter
Plasma
creatinine
moles/liter
Plasma
urea:creatinine
ratio
Serum
transferrin
mg/dl
Pre-treatment 2.39 1.51 496 26.4 513
1 month 2.54d 1.03' 271" 17.3' 507 33.0" 238
6 months 2.68b 1.17a l39 20.1' 575 33.9 290"
12 months 2.65" 1.29 — l5.9 519 3l.0 —
P<0.05 -
bp<002 I
'P <0.01 compared to pre-treatment.
P < o.oosi
Body composition. (Fig. 2). After six months of EAA/KAA
treatment there was a significant increase in TBW (mean pre-
EAAIKAA 12.65 liters 3.9 SD, mean post-EAA/KAA 14.22
liters 4.01 SD, P < 0.01), but no significant change in ECV
(mean pre-EAA/KAA 5.09 liters 1.11 SD, mean post-EAA/
KAA 5.36 liters 1.15 SD, P > 0.1). ICW increased significant-
ly (mean pre-EAA/KAA 7.55 liters 2.55 SD, mean post-
EAA/KAA 8.85 liters 3.1 SD, P <0.05). When observed ICW
was expressed as a fraction of predicted ICW, values increased
in five children, were unchanged in one, and fell in one child.
The mean increase was not statistically significant (mean pre-
EAA/KAA 1.10 0.18 SD, mean post-EAA/KAA 1.20 0.24
SD, P > 0.1).
Metabolic effects
Calcium and phosphate metabolism. In all children dietary
intake of calcium increased and intake of phosphate decreased
during treatment (Table 1), Mean values for plasma calcium,
phosphate and serum PTH before and during EAAIKAA treat-
ment are shown in Table 4. Plasma calcium rose in all children
(Fig. 3) despite temporary discontinuation of Vitamin D; plasma
phosphate fell significantly. Patients numbered 1 and 6 devel-
oped hypercalcemia necessitating interruption of EAA/KAA
for 1 week after 6 and 4 months of treatment, respectively. In
these children EAAIKAA were subsequently restarted at 75%
of the previous dosage. Calcium x phosphate product fell
significantly at 1 month (mean 3.61 mmoles2/liter2 0.37 SD
pre-EAA/KAA, 2.62 mmoles2/liter2 0.91 SD at 1 month, P <
0.02) but was not significantly different from pretreatment after
6 and 12 months. Mean serum PTH in control children was 85
71 sr (range, 0 to 215) pg!ml. Levels fell in all children during
EAA/KAA (Fig. 3). Pooled data for serum PTH showed a
significant inverse correlation with plasma calcium (r = —0.512,
N = 43, P < 0.001) (Fig. 3) and a positive but less significant
correlation with plasma phosphate concentration (r = 0.327, N
= 43, P < 0.05). Plasma alkaline phosphatase did not change
significantly during treatment. Five children showed no radio-
logical evidence of renal osteodystrophy before or during
EAA/KAA treatment: Patient no. 1 had mild changes of hyper-
parathyroidism which remained stable throughout the study
period. Patient no. 6 developed radiological evidence of mild
hyperparathyroidism during the second 6 months of treatment.
Despite not receiving supplementary vitamin D, her growth
velocity during EAA/KAA showed a marked increase, although
this was less in the second 6 months of treatment. Her serum
PTH levels were normal at the beginning of treatment and rose
only marginally toward the end of the treatment period (Fig. 3).
Aminoacid and ketoacid levels. Mean blood levels of amino-
acids and ketoacids are shown for control children and study
children before and during the first 6 months of treatment in
Table 5. During pretreatment there were significant reductions
compared to control children for plasma valine, leucine, total
BCAA, threonine, lysine, serine, aminobutyric acid, valine/gly-
cine, tyrosine/phenylalanine ratios, serum KICA, and total
BCKAA. There were significant elevations compared to control
children for plasma citrulline, proline, and 1- and 3-methylhisti-
dine. During EAA/KAA treatment these variations from normal
remained essentially unchanged. Compared to pretreatment,
there was a significant reduction in plasma isoleucine after 1
month of EAA/KAA treatment. After 6 months the levels of
BCAA, BCKAA, and all other AA were unchanged with the
exception of alloisoleucine, which had accumulated and persist-
ed in the plasma of all children during treatment.
Nitrogen balance. Nitrogen balance improved from a mean
of +1.29 g!day to +1.5 g/day in patient no. 5, and from +1.52
glday to +2.16 g/day in patient no. 6. Fractional phosphate
excretion during the balance studies decreased from 0.66 to 0.35
in patient no. 5 (serum PTH fell from 450 to 250 pg/mI) and from
0.42 to 0.06 in patient no. 6 (serum FFH fell from 150 to 0
pg!ml).
Following EAAIKAA blood urea and urea:creatinine ratios
fell in all children and mean values remained significantly below
pretreatment values (Table 4). GFR (Table 1) and plasma
creatinine (Table 4) did not change significantly during the
study. Mean serum transferrin was increased significantly after
6 months; mean plasma albumin was unchanged.
Discussion
Poor linear growth is a major problem for children with CRF,
and although improvement may occur on regular dialysis or
following renal transplantation, growth often remains poor on
both these modalities of treatment [11]. Final height, therefore,
may depend critically on growth while on conservative treat-
ment, particularly in early childhood when height velocity is
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ments for growth in experimental uremia may be increased [31].
The degree of protein restriction which allows maximum effica-
cy of KAA and reduction in uremic toxicity while permitting
normal or catch-up growth in children with CRF is unknown, as
is the optimum dosage and formulation of both EAA and KAA
supplements. In the present study total protein intake was
reduced to MRP [14], which includes both an allowance for 70%
net protein utilization and a further 20% for individual variation
in nitrogen requirements over and above those calculated for
basal metabolism and normal growth. The dose of EAA/KAA
supplement per kilogram of body weight was similar [4, 5, 9] or
greater [6, 32, 33] compared to that used in most adult studies.
The supplement was formulated to closely resemble human
breast milk with an excess of KAA based on an efficiency of
transamination of EAA of 50%. This figure was an approxima-
tion based on available evidence [2, 34] but is likely to vary
widely for different KAA' s and according to other factors
including rate of absorption and dietary composition [2, 34].
However, while transamination of KAA to EAA may be of
some therapeutic value in uremia by supplying EAA for protein
synthesis at the expense of endogenous nonessential nitrogen,
other metabolic effects of KAA may be of equal or greater
importance [1, 2]. In particular, the sparing effect on nitrogen
wasting observed in starved obese adults both during and for
several days after the intravenous administration of the KAA of
leucine, isoleucine, and valine indicates more profound effects
__________________________________
of these compounds than simple transamination [35]. The more
recent finding that this effect may be achieved by KICA alone
[36] is of particular interest considering the in vitro effects on
muscle protein metabolism attributed to leucine [37] and KICA
[38]. In this context it is worthy of note that KICA is the
predominant component of our EAA/KAA supplement and that
of others, and it may be worthwhile investigating whether
KICA alone might benefit protein-restricted uremic patients to
a similar degree as currently available mixtures.
Variations compared to normal children of plasma aminoacid
levels described in the present study are similar to those
previously reported in uremic children either on conservative
treatment [39] or on regular hemodialysis [25] and were essen-
tially unchanged during EAA/KAA treatment. Mean plasma
aminoacid levels did not change during supplementation with
the exception of isoleucine which fell significantly after 1
month. This fall has been demonstrated previously in both
adults and children given large doses of MEVA [40] and may
reflect the fact that commercial preparations of MEVA are a
racemic mixture of two stereoisomers. These are designated
S(+) and R(—) and are the a-ketoanalogues of L-isoleucine and
L-alloisoleucine, respectively. The presence of this latter com-
pound in the fasting plasma aminogram of patients on KAA
suggests that interconversion of the carbon skeletons of L-
isoleucine and L-alloisoleucine by enolization of the corre-
sponding a-ketoacids is relatively slow in contrast to previous
findings in dogs [41]. Although it has been previously empha-
sized that alloisoleucine is nontoxic and is not incorporated into
body protein [3], it has also been shown to be completely
ineffective as a substitute for isoleucine in rats [42]. Further-
more, doubts previously have been cast on the ability of
children in particular to convert the R(—) isomer to isoleucine
[1]. In view of these considerations, the calculated dose of
MEVA in our supplement could have been underestimated,
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Fig. 3. Changes in plasma calcium and serum PTH during EAA/KAA
treatment and (lower graph) plot of plasma calcium versus serum PTH.
Range of serum PTH forcontrol children is shown by shaded area.
normally greatest [29]. The present study suggests that a
protein-restricted diet supplemented with EAA and the calcium
salts of KAA may allow normal and sometimes supranormal
growth in prepubertal uremic children and that this is associated
with a reduction in hyperparathyroidism, and improved protein
anabolism as reflected by changes in body cell mass, upper arm
circumference, serum transferrin, and nitrogen balance.
Although studies in uremic adults [1, 9] and rats [30] suggest
that KAA are nutritionally most effective when nitrogen is
restricted markedly, there is evidence that the nitrogen require-
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Table 5. Blood aminoacid and ketoacid levels before and dunng treatment (mo1es/1iter SD)
Controls
(N = 8)
Patients (N = 7)
Pre-EAAIKAA I month 6 months
Valine 211 37 156 32c 128 44 127 32
Leucine 109 14 81 22b 68 22 81 20
Isoleucine 55 5 52 13 43 13 43 16
Total BCAA 361 68 289 61a 240 67 259 62
KIVA 11 2 9 4 8 2 7 3
KICA 42 9 25 7d 23 7 25 6
MEVA 20 5 17 5 16 5 16 4
Total BCKAA 74 15 51 j5b 46 9 49 12
Alanine 358 128 385 142 274 77 266 47
Threonjne 138 34 90 37a 101 42 73 24
Glycine 218 56 286 127 263 66 221 42
Citrulline 33 8 87 24 108 42 109 27
Cystine 44 7 39 16 39 16 37 13
Methionine 21 6 19 12 19 II 15 5
Tyrosine 66 8 43 15 39 14 37 7
Phenylalanine 46 4 51 9 47 13 50 13
Ornithine 44 18 43 12 41 8 48 11
Lysine 159 28 112 17" 113 26 112 29
Arginine 100 22 80 18 78 19 88 32
Taunne 96 61 100 38 82 49 122 61
Aspartic acid 16 3 28 18 27 20 22 5
Serine 108 12 78 19d 79 14 60 20
Proline 137 23 252 102" 179 66 181 69
a-Aminobutyrate 18 8 9 5 6 5 10 5
Histidine 79 10 75 33 79 36 63 8
1-Methyihistidine ND 48 52 35 41 47 16
3-Methylhistidine ND 25 15 20 10 23 20
Alloisoleucine ND ND 27 18 22 13
Valine/glycine 1.02 0.36 0.64 0.29 0.53 0.32 0.60 0.22
Tyrosine/phenylalanine 1.43 0.07 0.78 0.30 0.81 0.29 0.74 0.26
Abbreviations: ND, not detected; other abbreviations are in Table 2.
P < 0.05
b P < 0.02
P < 0.01 compared to control children.
P < 0.005
P < 0.001
P < 0.05 compared to pre-treatment values.
perhaps by as much as 50%. Walser [1] has suggested that only
the pure S(+) isomer of MEVA be used in young children and
infants.
Serum levels of KAA have not previously been described in
children with CRF on conservative treatment. The tendency to
reduced BCKAA levels, highly significant in the case of KICA,
is similar to that previously described in adults on conservative
treatment by Shauder et al [33] but less marked than the
reductions in BCKAA found by these investigators in adults on
dialysis and by ourselves in adolescents on regular hemodialy-
sis [43]. In the latter study we found reduced levels of KICA
and MEVA and also significant reductions compared to control
children for the ratio of KAA to EAA, suggesting alteration in
the equilibrium between these compounds in uremia. In neither
the present study nor that of Shauder et at [33] was dietary
treatment with EAA/KAA supplementation associated with any
return toward normal blood aminoacid or ketoacid profiles.
In this regard our diet must be considered ineffective. However,
in the case of EAA, intracellular rather than plasma abnormali-
ties may be of greater significance, and the importance of
correcting these by appropriately formulated EAA supplements
has been suggested by FUrst, Alvesstrand, and Bergstrom [44].
Such considerations may also apply in the case of KAA, but, to
our knowledge, measurements of their intracellular concentra-
tions and intracellular disturbances in KAA/EAA equilibrium
are not available for uremic subjects.
We did not consider it feasible to perform either a double
blind or cross-over study of KAA in children with advanced
CRF. It is therefore likely that, in addition to the effects of
EAAIKAA, a number of other alterations produced by our
study diet contributed to some of the changes seen. In particu-
lar, treatment was associated with a fall in plasma urea and
phosphate levels as a consequence of increased anabolism and a
reduction in nitrogen and phosphate intake. Evidence suggests
that both nitrogen and phosphate are important uremic toxins,
the latter largely as a result of its stimulatory effect on the
secretion of PTH [45]. The fall in plasma phosphate in the
present study, together with a rise in plasma calcium resulting
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from an increased total dietary calcium intake (the KAA being
taken as their calcium salts), was associated with a highly
significant reduction in serum PTH; levels fell and remained in
the normal range when plasma calcium was 2.6 mmoles or over
(Fig. 3). The fall in fractional urinary excretion of phosphate
during the nitrogen balance studies further attests to a reduction
in hyperparathyroidism on KAA treatment. Although we were
concerned to prevent severe hypercalcemia, plasma phosphate
fell in most children and calcium x phosphate product was
either reduced or unchanged compared to pretreatment. Previ-
ous studies emphasized the beneficial effects of reducing plas-
ma phosphate and PTH by protein restriction either with [5, 6]
or without [45—47] KAA supplements, particularly with regard
to preservation or even improvement in renal function [5, 6, 47].
In the present study it is worthy of note that, in a group of
children where some deterioration of renal function might be
expected over a 12-month period, during EAA/KAA treatment
there was no significant alteration in plasma creatinine despite
increase in body cell mass; no significant change in GFR was
corrected for body surface area. These findings suggest that the
study diet may have resulted in some preservation of renal
function, although we have insufficient data on change in GFR
during the preceding 12 months to confirm this irrefutably.
In conclusion, we emphasize that our observations are pre-
liminary and limited by the absence of a suitable control group
of children. It is also important to note that although linear
growth on EAA/KAA improved compared to pretreatment in
all children, supra-normal or catch-up growth as evidenced by
an increase in height SDS in relation to bone age, was modest in
most cases. It therefore follows that either prolonged dietary
treatment, or the initiation of therapy early in childhood before
growth potential has been lost [291, is likely to produce the
greatest improvement in final height. We have previously found
that rigid dietary prescription is poorly tolerated by uremic
children, a particular difficulty of which is the maintenance of
an adequate energy intake in the face of severe or even
moderate protein restriction [26]. However, in this respect the
nitrogen-free KAA offer some advantages over EAA by allow-
ing a higher intake of nonessential nitrogen and therefore a
more liberal and palatable diet. The sustained fall in blood urea
and urea:creatinine ratio in the present study suggests that
dietary tolerance was good. Whether long-term therapy with
protein-restricted diets and EAA/KAA supplements will prove
generally acceptable to infants and children with CRF, usefully
affect final height, or allow any preservation of renal function,
remains to be established.
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